Participated · Equity · May 2026

Windward Bio was launched in January 2025 and is developing a portfolio of long-acting antibody therapeutics targeting validated immunological drivers. Its lead program, WIN378, is a next-generation, fully human anti-TSLP monoclonal antibody engineered for half-life extension and silenced effector function; WIN378 completed Phase 1, is dosed subcutaneously, and is being evaluated in the Phase 2/3 POLARIS asthma trial with initial data expected in the second half of 2026. A Phase 2 study of WIN378 in COPD is anticipated to start in Q2 2026 and the first Phase 3 study is expected to begin in Q4 2026. WIN027 is a long-acting bispecific (TSLPxIL-13) currently in Phase 1 with data expected by year-end 2026 and is planned for proof-of-concept studies across respiratory and dermatology indications beginning Q4 2026. The company has in-licensed global rights for its programs from partners including Kelun-Biotech/Harbour BioMed and Qyuns Therapeutics, and is building a discovery pipeline of long-acting bispecific antibodies. Windward has raised $365M since launch and intends to use the new financing to extend its runway and accelerate multiple clinical readouts and study starts.

Participated · Series A · Apr 2026

Vivacta is developing next-generation in vivo CAR-T therapies, with its lead program GT801 focused on hematologic malignancies and autoimmune diseases. Early clinical data reported at ASH 2025 indicated promising safety and efficacy signals for GT801. The company plans to use new financing to advance GT801 clinical trials, pursue regulatory submission and approval, expand its research team and platform, and drive global expansion. Vivacta describes its investor base as a mix of global industrial capital and specialist biotech investors, and raised over US$50 million in its Series A and Series A+ financings. After the financing, representatives from Loyal Valley Capital and DC Global Ventures joined the board, signaling investor engagement in governance and strategy.

Participated · Series D · Apr 2026

Pulnovo Medical develops a Pulmonary Artery Denervation (PADN) system, a minimally invasive interventional therapy targeting over‑activated sympathetic nerve activity implicated in pulmonary vascular remodeling and cardiopulmonary disease progression. Multiple global studies and inclusion in international guidelines (including the 2022 ESC/ERS Guidelines) support PADN’s clinical benefits in improving functional capacity and reducing major adverse events. The company reports approximately 1,500 PADN procedures performed globally and regulatory approvals in seven countries, while actively promoting commercialization in the EU, Middle East, and China. In the U.S., Pulnovo has received FDA Breakthrough Device Designation and launched two fully approved IDE clinical trials led by Professor Gregg Stone. Pulnovo is pursuing further clinical evidence (including the PULSE‑LHD IDE trial) and is expanding its global clinical, regulatory, and commercial footprint, including a commercial cooperation agreement with Medtronic. The recent financing will fund continued clinical R&D, global regulatory filings, international commercialization, and investment in the core technology platform.

Participated · Equity · Apr 2026

Pulnovo Medical develops a proprietary Pulmonary Artery Denervation (PADN) System, a minimally invasive therapy aimed at modulating sympathetic nerve activity implicated in pulmonary vascular remodeling and cardiopulmonary disease progression. The company reports about 1,500 PADN procedures performed globally and regulatory approvals in seven countries, and it is advancing commercialization across the European Union, Middle East, and China. Pulnovo's therapy has been referenced in multiple international clinical guidelines, including the 2022 ESC/ERS Guidelines, and clinical studies are ongoing in Europe and Asia with U.S. IDE trials recently initiated. In the United States the company has received FDA Breakthrough Device designation and has started two fully approved IDE trials, including the PULSE-LHD trial. Following the $100 million strategic financing led by Medtronic, Pulnovo plans to use proceeds to support clinical development, regulatory submissions, international commercialization, and continued technology investment. The company is also expanding its leadership team, hiring a Chief Strategy Officer to strengthen ties with global capital markets and industry partners.

Led · Equity · Apr 2026

Oricell leverages a proprietary technology triad—Ori®Ab antibody discovery, Ori®Armoring T-cell enhancement, and OnGo CMC rapid manufacturing—to develop a diversified pipeline of cell therapies targeting solid tumors and hematologic malignancies. Its lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T for advanced hepatocellular carcinoma that has completed investigator-initiated trials and a registrational Phase 1 and is preparing for pivotal trials, with clinical readouts highlighted at major forums including ASCO. Another core candidate, OriCAR-017, advanced from IIT in China to global development, securing IND approvals from China NMPA and the US FDA as well as FDA Orphan Drug and Fast Track designations. Oricell has presented data at multiple global conferences (including ASCO and EHA) and published results in The Lancet Haematology. The company states the programs have demonstrated favorable safety and robust efficacy in IIT and registrational trials, supporting its global regulatory and clinical strategy.